- Show all
- Alicaforsen - review papers
- Alicaforsen - treatment case series papers
- Alicaforsen - Phase 2 Data
- Antisense
- Inflammatory Bowel Disease
- ICAM-1
- Renzapride - Irritable Bowel Syndrome Phase 2 Data
- Renzapride - Irritable Bowel Syndrome Phase 3 Data
- Renzapride in Systemic Scleroderma - Overall Disease Pathology
- Renzapride in Systemic Scleroderma - Gastrointestinal Involvement
- Renzapride in Cystic Fibrosis - Gastrointestinal Involvement
- Renzapride in Cystic Fibrosis - Therapeutic Effect of "Prides"
- Renzapride in Gastroparesis Phase 2 Data
Alicaforsen for the treatment of inflammatory bowel disease
V. Jairath, R. Khanna, B.G. Feagan
Expert Opin Investig Drugs 2017 Jul 6:1-7
Disclaimer
The information in “published papers” is provided by Atlantic Healthcare plc, and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.